DENALI THERAPEUTICS INC
NASDAQ: DNLI (Denali Therapeutics Inc.)
Last update: 6 hours ago20.79
1.25 (6.40%)
| Previous Close | 19.54 |
| Open | 19.84 |
| Volume | 1,861,250 |
| Avg. Volume (3M) | 1,790,146 |
| Market Cap | 3,299,575,808 |
| Price / Sales | 3.64 |
| Price / Book | 3.45 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -2.64 |
| Total Debt/Equity (MRQ) | 4.59% |
| Current Ratio (MRQ) | 9.56 |
| Operating Cash Flow (TTM) | -365.54 M |
| Levered Free Cash Flow (TTM) | -257.54 M |
| Return on Assets (TTM) | -22.58% |
| Return on Equity (TTM) | -35.21% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Denali Therapeutics Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | 1.5 |
| Price Volatility | -4.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | 0.40 |
|
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 9.86% |
| % Held by Institutions | 94.15% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 19.66 | - | 12,816 | 251,963 |
| COOK JENNIFER E. | 19.66 | - | 6,408 | 125,981 |
| FLATLEY JAY T | 19.66 | - | 6,408 | 125,981 |
| KLEIN PETER S | 19.66 | - | 6,408 | 125,981 |
| KROGNES STEVE E. | 19.66 | - | 6,408 | 125,981 |
| SCHENKEIN DAVID P | 19.66 | - | 6,408 | 125,981 |
| THORNBERRY NANCY | 19.66 | - | 6,408 | 125,981 |
| VAN HAUWERMEIREN TIMOTHY | 19.66 | - | 6,408 | 125,981 |
| Aggregate Net Quantity | 57,672 | |||
| Aggregate Net Value ($) | 1,133,832 | |||
| Aggregate Avg. Buy ($) | 19.66 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | Director | 03 Jun 2026 | Acquired (+) | 12,816 | 19.66 | 251,963 |
| COOK JENNIFER E. | Director | 03 Jun 2026 | Acquired (+) | 6,408 | 19.66 | 125,981 |
| VAN HAUWERMEIREN TIMOTHY | Director | 03 Jun 2026 | Acquired (+) | 6,408 | 19.66 | 125,981 |
| THORNBERRY NANCY | Director | 03 Jun 2026 | Acquired (+) | 6,408 | 19.66 | 125,981 |
| SCHENKEIN DAVID P | Director | 03 Jun 2026 | Acquired (+) | 6,408 | 19.66 | 125,981 |
| KROGNES STEVE E. | Director | 03 Jun 2026 | Acquired (+) | 6,408 | 19.66 | 125,981 |
| KLEIN PETER S | Director | 03 Jun 2026 | Acquired (+) | 6,408 | 19.66 | 125,981 |
| FLATLEY JAY T | Director | 03 Jun 2026 | Acquired (+) | 6,408 | 19.66 | 125,981 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |